Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zefeng Xu

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
Blood Cancer Journal|April 20, 2023
Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progressionXin Yan, Zefeng Xu, Peihong Zhang, et al.
Oncotarget|December 2, 2016
Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromesJingya Wang, Xiaofei Ai, Tiejun Qin, et al.
Experimental Hematology & Oncology|April 30, 2016
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromesGege Feng, Robert Peter Gale, Wen Cui, et al.
Haematologica|October 21, 2017
Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse modelsJieyu Wang, Yoshihiro Hayashi, Asumi Yokota, et al.
Stem Cell Investigation|October 26, 2016
<i>TET2</i> mutations were predictive of inferior prognosis in the presence of <i>ASXL1</i> mutations in patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
British Journal of Haematology|December 28, 2022
Impact of the International Consensus Classification of myelodysplastic syndromesYudi Zhang, Junying Wu, Zefeng Xu, et al.
Experimental Hematology & Oncology|October 17, 2022
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromesJunying Wu, Yudi Zhang, Tiejun Qin, et al.
Experimental Hematology & Oncology|May 29, 2015
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Oncotarget|September 23, 2016
Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-RBing Li, Jinqin Liu, Shiqiang Qu, et al.
Blood Cancer Journal|September 18, 2021
Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia veraDan Liu, Zefeng Xu, Peihong Zhang, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Blood Cancer Journal|April 20, 2023
Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progressionXin Yan, Zefeng Xu, Peihong Zhang, et al.
Oncotarget|December 2, 2016
Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromesJingya Wang, Xiaofei Ai, Tiejun Qin, et al.
Experimental Hematology & Oncology|April 30, 2016
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromesGege Feng, Robert Peter Gale, Wen Cui, et al.
Haematologica|October 21, 2017
Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse modelsJieyu Wang, Yoshihiro Hayashi, Asumi Yokota, et al.
Stem Cell Investigation|October 26, 2016
<i>TET2</i> mutations were predictive of inferior prognosis in the presence of <i>ASXL1</i> mutations in patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
British Journal of Haematology|December 28, 2022
Impact of the International Consensus Classification of myelodysplastic syndromesYudi Zhang, Junying Wu, Zefeng Xu, et al.
Experimental Hematology & Oncology|October 17, 2022
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromesJunying Wu, Yudi Zhang, Tiejun Qin, et al.
Experimental Hematology & Oncology|May 29, 2015
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Oncotarget|September 23, 2016
Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-RBing Li, Jinqin Liu, Shiqiang Qu, et al.
Blood Cancer Journal|September 18, 2021
Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia veraDan Liu, Zefeng Xu, Peihong Zhang, et al.
Pageof 13